Degradation of fibrillar collagen in a human melanoma xenograft improves the efficacy of an oncolytic herpes simplex virus vector.
暂无分享,去创建一个
Wilson Mok | Moungi G Bawendi | George Alexandrakis | Rakesh K Jain | P. Grandi | R. Jain | Y. Boucher | M. Bawendi | X. Breakefield | G. Alexandrakis | T. McKee | J. P. Zimmer | Xandra O Breakefield | Yves Boucher | N. Insin | Trevor D McKee | Numpon Insin | Paola Grandi | John P Zimmer | Wilson Mok
[1] P. Grandi,et al. Degradation of fibrillar collagen in a human melanoma xenograft improves the efficacy of an oncolytic herpes simplex virus vector. , 2006, Cancer Research.
[2] T. Cripe,et al. Widespread intratumoral virus distribution with fractionated injection enables local control of large human rhabdomyosarcoma xenografts by oncolytic herpes simplex viruses , 2005, Cancer Gene Therapy.
[3] Bart Everts,et al. Replication-selective oncolytic viruses in the treatment of cancer , 2005, Cancer Gene Therapy.
[4] Qun Zhou,et al. Viral vectors for cancer gene therapy: viral dissemination and tumor targeting. , 2005, Current gene therapy.
[5] R. Jain,et al. Incorporation of Luminescent Nanocrystals into Monodisperse Core–Shell Silica Microspheres , 2004 .
[6] D. Carbone,et al. Combination Therapy with Conditionally Replicating Adenovirus and Replication Defective Adenovirus , 2004, Cancer Research.
[7] D. Tarin,et al. Altered Metastatic Behavior of Human Breast Cancer Cells after Experimental Manipulation of Matrix Metalloproteinase 8 Gene Expression , 2004, Cancer Research.
[8] Brian Seed,et al. Dynamic imaging of collagen and its modulation in tumors in vivo using second-harmonic generation , 2003, Nature Medicine.
[9] E. Chiocca,et al. Comparative analyses of transgene delivery and expression in tumors inoculated with a replication-conditional or -defective viral vector. , 2001, Cancer research.
[10] W. Rom,et al. Wild-type adenovirus decreases tumor xenograft growth, but despite viral persistence complete tumor responses are rarely achieved--deletion of the viral E1b-19-kD gene increases the viral oncolytic effect. , 2001, Human gene therapy.
[11] R. B. Campbell,et al. Role of tumor–host interactions in interstitial diffusion of macromolecules: Cranial vs. subcutaneous tumors , 2001, Proceedings of the National Academy of Sciences of the United States of America.
[12] R. Weinberg,et al. Heterotypic signaling between epithelial tumor cells and fibroblasts in carcinoma formation. , 2001, Experimental cell research.
[13] M. Israel,et al. Protease pretreatment increases the efficacy of adenovirus-mediated gene therapy for the treatment of an experimental glioblastoma model. , 2001, Cancer research.
[14] F. Khuri,et al. Phase II trial of intratumoral administration of ONYX-015, a replication-selective adenovirus, in patients with refractory head and neck cancer. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[15] J. Lavail,et al. Retrograde axonal transport of herpes simplex virus: evidence for a single mechanism and a role for tegument. , 2000, Proceedings of the National Academy of Sciences of the United States of America.
[16] R. Martuza,et al. Conditionally replicating herpes simplex virus mutant, G207 for the treatment of malignant glioma: results of a phase I trial , 2000, Gene Therapy.
[17] R. Jain,et al. Role of extracellular matrix assembly in interstitial transport in solid tumors. , 2000, Cancer research.
[18] A. Jacobs,et al. Therapeutic efficiency and safety of a second-generation replication-conditional HSV1 vector for brain tumor gene therapy. , 1997, Human gene therapy.
[19] N. DeLuca,et al. Functional interactions between herpes simplex virus immediate-early proteins during infection: gene expression as a consequence of ICP27 and different domains of ICP4 , 1995, Journal of virology.
[20] R. Martuza,et al. Transfer and expression of the lacZ gene in rat brain neurons mediated by herpes simplex virus mutants. , 1990, The New biologist.
[21] D. Kirn,et al. Oncolytic Viruses: Methods and Protocols , 1972, Nature.